Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
The COVID-19 pandemic continues to spread in the U.S. and around the world. COVI-VAC is a single-dose, intranasal, live attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.
RSV hospitalizations among adults 65+ no vaccine
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
September 22, 2021
Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies
Novel intranasal vaccine candidate shows promise for immunity against COVID-19 and virus variantsFull Story
August 26, 2021
Codagenix Appoints Tyler Cook as Chief Financial Officer
Veteran life sciences executive brings over 20 years finance and operations expertiseFull Story